Tags

Type your tag names separated by a space and hit enter

Impact of desmopressin on nocturia due to nocturnal polyuria in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH).
World J Urol. 2014 Oct; 32(5):1163-70.WJ

Abstract

PURPOSE

To evaluate the efficacy of desmopressin on nocturia, quality of sleep (QoS), and health-related quality of life (HRQoL) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) and nocturia due to nocturnal polyuria (NP) as the predominant symptom.

METHODS

A German observational, multicenter, post-marketing surveillance study including men with LUTS/BPH and nocturia due to NP starting 3 months of desmopressin treatment.

RESULTS

In total, 137 patients with a mean of 3.8 nocturnal voids (range 2-7) were included. Desmopressin significantly reduced the mean number of nocturnal voids by 53 %, mean IPSS nocturia question by 50 %, and the mean ratio of night/24-h urine volume by 39 % from baseline to endpoint. The hours of undisturbed sleep significantly increased by 74 %; 71 % of men reported about undisturbed sleep of ≥4 h at study end. Additionally, there was a significant reduction in the Leeds Sleep Evaluation Questionnaire score, indicating a clinically relevant QoS improvement. This was associated with an improved HRQoL, as shown by a significant improvement in both the mean IPSS-QoL question by 43 % and mean ICIQ-N nocturia problem question by 53 %. Concomitant alpha-blocker use had no effect on the efficacy of desmopressin. The incidence of adverse events was low (2.2 %). Hyponatremia was not observed in any patient. The majority of patients and physicians rated the efficacy and tolerability of desmopressin as good/very good.

CONCLUSIONS

Desmopressin is an effective and well-tolerated treatment for nocturia due to NP in patients with LUTS/BPH in daily practice under routine conditions.

Authors+Show Affiliations

PAN-Klinik am Neumarkt, Cologne, Germany.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25135845

Citation

Berges, Richard, et al. "Impact of Desmopressin On Nocturia Due to Nocturnal Polyuria in Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)." World Journal of Urology, vol. 32, no. 5, 2014, pp. 1163-70.
Berges R, Höfner K, Gedamke M, et al. Impact of desmopressin on nocturia due to nocturnal polyuria in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). World J Urol. 2014;32(5):1163-70.
Berges, R., Höfner, K., Gedamke, M., & Oelke, M. (2014). Impact of desmopressin on nocturia due to nocturnal polyuria in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). World Journal of Urology, 32(5), 1163-70. https://doi.org/10.1007/s00345-014-1381-7
Berges R, et al. Impact of Desmopressin On Nocturia Due to Nocturnal Polyuria in Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH). World J Urol. 2014;32(5):1163-70. PubMed PMID: 25135845.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of desmopressin on nocturia due to nocturnal polyuria in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). AU - Berges,Richard, AU - Höfner,Klaus, AU - Gedamke,Michael, AU - Oelke,Matthias, Y1 - 2014/08/19/ PY - 2014/08/06/received PY - 2014/08/08/accepted PY - 2014/8/20/entrez PY - 2014/8/20/pubmed PY - 2015/10/31/medline SP - 1163 EP - 70 JF - World journal of urology JO - World J Urol VL - 32 IS - 5 N2 - PURPOSE: To evaluate the efficacy of desmopressin on nocturia, quality of sleep (QoS), and health-related quality of life (HRQoL) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) and nocturia due to nocturnal polyuria (NP) as the predominant symptom. METHODS: A German observational, multicenter, post-marketing surveillance study including men with LUTS/BPH and nocturia due to NP starting 3 months of desmopressin treatment. RESULTS: In total, 137 patients with a mean of 3.8 nocturnal voids (range 2-7) were included. Desmopressin significantly reduced the mean number of nocturnal voids by 53 %, mean IPSS nocturia question by 50 %, and the mean ratio of night/24-h urine volume by 39 % from baseline to endpoint. The hours of undisturbed sleep significantly increased by 74 %; 71 % of men reported about undisturbed sleep of ≥4 h at study end. Additionally, there was a significant reduction in the Leeds Sleep Evaluation Questionnaire score, indicating a clinically relevant QoS improvement. This was associated with an improved HRQoL, as shown by a significant improvement in both the mean IPSS-QoL question by 43 % and mean ICIQ-N nocturia problem question by 53 %. Concomitant alpha-blocker use had no effect on the efficacy of desmopressin. The incidence of adverse events was low (2.2 %). Hyponatremia was not observed in any patient. The majority of patients and physicians rated the efficacy and tolerability of desmopressin as good/very good. CONCLUSIONS: Desmopressin is an effective and well-tolerated treatment for nocturia due to NP in patients with LUTS/BPH in daily practice under routine conditions. SN - 1433-8726 UR - https://www.unboundmedicine.com/medline/citation/25135845/Impact_of_desmopressin_on_nocturia_due_to_nocturnal_polyuria_in_men_with_lower_urinary_tract_symptoms_suggestive_of_benign_prostatic_hyperplasia__LUTS/BPH__ L2 - https://dx.doi.org/10.1007/s00345-014-1381-7 DB - PRIME DP - Unbound Medicine ER -